Table 2.

Table displaying the incidence of adverse effects (AE) in patients receiving Evo 670 mg/m² in combination with Bevacizumab 10 mg/kg IV every 2 weeks (n = 35).

Adverse effect	All grades incidence (%) (n = 35)	Number of patients with grade 3 AE or higher (%)
Mucositis	43	5 (14)
Fatigue	34	1 (3)
Rash	26	0 (0)
Thrombocytopenia	20	2 (6)
Nausea	17	0 (0)
Skin ulceration	17	1 (3)
Hyperpigmentation	17	0 (0)

Adverse effects with all grades incidence lower than 10% are not included in this table, Grade 2 Anemia had highest incidence among this group (2%) with no reported Grade 3 or higher Anemia.